Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and p... Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine. Show more
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration forΒ TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 1.5 | 2 | 2.23 | 1.88 | 531260 | 2.07516288 | CS |
4 | -0.86 | -29.7577854671 | 2.89 | 2.9713 | 1.88 | 442392 | 2.28850919 | CS |
12 | -1.08 | -34.7266881029 | 3.11 | 4.06 | 1.88 | 371541 | 2.80264414 | CS |
26 | -2.66 | -56.7164179104 | 4.69 | 5.32 | 1.88 | 347659 | 3.44658179 | CS |
52 | -0.77 | -27.5 | 2.8 | 7.01 | 1.66 | 429089 | 3.6885866 | CS |
156 | -16.22 | -88.8767123288 | 18.25 | 32 | 1.64 | 323944 | 5.11040311 | CS |
260 | -17.47 | -89.5897435897 | 19.5 | 32 | 1.64 | 323466 | 5.83617133 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.